ESH CLL 2022 | Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, shares some recent updates on non-covalent Bruton’s tyrosine kinase (BTK) inhibitors and their place in chronic lymphocytic leukemia (CLL) treatment, drawing focus on pirtobrutinib and nemtabrutinib. Dr Mato first discusses some results from the use of pirtobrutinib in CLL and other B-cell malignancies, including response rates, progression-free survival (PFS) and the impressive safety profile of this novel agent. Dr Mato then discusses the use of nemtabrutinib, including the activity, duration of response, and adverse events associated with this molecule. To conclude, Dr Mato highlights that while these agents have not yet been approved for CLL treatment, there are numerous ongoing clinical trials investigating their efficacy and various drug combinations, which are crucial for the future of CLL treatment. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Research support: TG Therapeutics, Pharmacyclics, Abbvie, Adaptive Biotechnologies, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, BeiGene, Genentech, Genmab, Janssen, Loxo Oncology, Nurix. Advisory/Consultancy/DSMB: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, Abbvie, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, AstraZeneca, BeiGene, Genentech, Janssen, Loxo Oncology
